
Baxter Cancer Drug Supply Crisis Compounds Earnings Weakness
Baxter faces EU cancer drug shortage extending to Q1 2027 amid disappointing 2026 earnings guidance, projecting $1.85-$2.05 EPS versus $2.25 consensus.
BAXearnings guidancesupply chain




Investing.com··Nathan Reiff






Investing.com··Jesse Cohen



Investing.com··Thomas Hughes
Investing.com··Chris Markoch